Prostate Knowledge Blog

Join in the conversation about common issues, breaking news, and research related to prostate health.

Men with locally advanced prostate cancer who combine hormone therapy with a course of radiation therapy tend to live longer than men who only take hormone therapy.

Read more »

Standard biopsies of the prostate gland often miss potentially aggressive prostate cancer. Adding MRI images to standard biopsies improves the detection of prostate cancer.

Read more »

A woman’s use of a testosterone-based vaginal cream may have contributed to a spike in her husband’s prostate-specific antigen and testosterone levels after he had his prostate removed to fight advanced prostate cancer.

Read more »

Men are at greater risk for developing prostate cancer if their fathers or brothers also developed the disease. A new study shows that having second- or third-degree relatives with the disease also increases a man’s risk.

Read more »

Although a long-term study has shown that men who had a vasectomy have a slightly increased risk of developed high-grade prostate cancer, not all experts believe that the link is real.

Read more »

A growing number of aging men are trying to hold on to their youthful vigor by taking testosterone. Unsettling study results suggest that men with low but “normal” testosterone levels who take a testosterone supplement may be increasing their risk of having a heart attack, stroke, or developing heart disease.

Read more »

Combining a chemotherapy drug called docetaxel with hormone therapy (androgen-deprivation therapy) to treat advanced prostate cancer appears to work better than starting with hormone therapy and adding docetaxel later.

Read more »

Prostate cancer tends to be more aggressive in men with low levels of vitamin D. Among African American men, low vitamin D is also linked to a higher risk of developing prostate cancer.

Read more »

A study published in the journal European Urology suggests that men who have defects in a cancer-suppressing gene known as BRCA are at high risk for aggressive prostate tumors, and so could benefit from PSA testing.

Read more »

An FDA advisory panel rejected a French company’s application to market high intensity focused ultrasound as a treatment for localized prostate cancer.

Read more »